Skip to content
Business websites
Business websites
Johnson & Johnson
J&J MedTech
Johnson & Johnson
J&J MedTech
Location
Language
English
Choose your local market.
Global
Global
English
North America
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
India
English
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Austria
Deutsch
Belgium
English
Français
Nederlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Nederlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
About us
Our Credo
Our responsibilities
Sustainability
Access and pricing principles
Social impact
Economic responsibility
Communicable diseases
Our leadership
Our heritage
Our awards
Our innovation
Focus areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Research & development
Our products
Our pipeline
Clinical trials
How we work
Patient engagement
Pre-approval access
Partnerships
Transparency
Careers
Search jobs
Life at J&J
Our teams
Locations
Student opportunities
How we hire
Newsroom
Press releases
Media contacts
Blogs
About us
Our Credo
Our responsibilities
Sustainability
Access and pricing principles
Social impact
Economic responsibility
Communicable diseases
Our leadership
Our heritage
Our awards
Our innovation
Focus areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Research & development
Our products
Our pipeline
Clinical trials
How we work
Patient engagement
Pre-approval access
Partnerships
Transparency
Careers
Search jobs
Life at J&J
Our teams
Locations
Student opportunities
How we hire
Newsroom
Press releases
Media contacts
Blogs
Menu
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Show Search
Newsroom
The latest news, information, and stories from Johnson & Johnson Innovative Medicine.
Press Releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
265 Results
265 Results
Open
Filters
Sort By
Newest
Newest
Relevance
Oldest
Oncology
First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select FGFR Alterations
October 22, 2023
Spain
Read more
Oncology
Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in OS in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone
October 22, 2023
Spain
Read more
Oncology
New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC
October 21, 2023
Spain
Read more
Oncology
Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) Vs Chemotherapy
October 21, 2023
Spain
Read more
Immunology
Janssen Announces TREMFYA® (guselkumab) Demonstrates Significant Skin Clearance in First-of-its-Kind Prospective, Large-Scale Study Dedicated to People of Color Living with Moderate to Severe Plaque Psoriasis
October 20, 2023
United States
Read more
Immunology
Janssen to Highlight Latest Research from Nipocalimab Clinical Development Program to Address Unmet Need in Myasthenia Gravis at AANEM 2023 Meeting
October 16, 2023
United States
Read more
Immunology
TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn’s Disease in a Phase 2 Study
October 16, 2023
United States
Read more
Oncology
Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO
October 16, 2023
United States
Read more
Immunology
Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress
October 9, 2023
United States
Read more
Oncology
Janssen Submits Application to the European Medicines Agency for RYBREVANT®▼ (amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon20ins Mutations
October 6, 2023
Belgium
Read more
Previous
16 of 27
Next
Featured stories
Connecting the best of Health&Care
Read more
Johnson & Johnson named a 2023 Fortune World’s Most Admired Company and ranked #1 on the Pharmaceutical Industry list
Read more
The power of precision medicine for patients
April 25, 2024
Gabriele Alegri
Read more
What is a gene mutation?
Read more
